Emerging niche business cluster eyes challenge
Manx-based BioMed Pharmacovigilance firm Panacea says there are risks posed by Brexit to the sector on the Isle of Man.
The company gathers, monitors and analyses medicines as they hit the market, and has been waxing lyrical about the Island's BioMed environment in the UK press recently.
It's been working within what it describes as the 'burgeoning' Manx cluster of specialist companies, and with the Isle of Man Government, to attract more enterprises to relocate here.
In the post-Brexit landscape, the firm sees both risks and opportunities.
Panacea business development manager Sam Tipper gave a corporate health check as Prime Minister Theresa May prepares to trigger the UK's EU exit:
Hospitality bosses to attend 'call to arms' meeting
Rate of inflation falls to 3.2%
Business will suffer 'significant' loss during the TT
TT merchandise provider makes upfront payment for contract
Hunt for new Steam Packet non-executives
Public disappointment after decision to sell ex-Newson's buildings
